专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07118905B2 Nucleic acid encoding angiogenesis inhibitor 有权
标题翻译：核酸编码血管生成抑制剂
公开(公告)号：US07118905B2
公开(公告)日：2006-10-10
申请号：US10849961
申请日：2004-05-19
申请人： Jihoon Chang , Jang Seong Kim , Eun Jeong Park , Jung-sun Yum , Soo-il Chung
发明人： Jihoon Chang , Jang Seong Kim , Eun Jeong Park , Jung-sun Yum , Soo-il Chung
IPC分类号： C12N1/20 , C12N15/09 , C12N15/63 , C07H21/04
CPC分类号： C07K14/4703 , A61K38/00
摘要： The present invention provides a novel angiogenesis inhibitor, LK68 whose amino acid sequence is identical with the human apolipoprotein (a) kringle domains IV36, IV37 and V38, a cDNA sequence encoding the LK68, a recombinant expression vector comprising the cDNA, a recombinant microorganism transformed with the recombinant expression vector and a novel use of the LK68 as an anticancer agent and a method for treating angiogenesis-mediated disease. LK68, LK6, LK7 and LK8 exhibit inhibitory activities on the cultured endothelial cell proliferation as well as on the endothelial cell migration. LK68 and its single kringles also inhibit the normal development of capillaries in the chick embryo chorioallantoic membrane (CAM). It was also showed that systemic administration of LK68 causes the inhibition of primary tumor growth, which is correlated with a suppression of tumor-induced angiogenesis. Accordingly, LK68 protein, its single kringles or their functional equivalents may be applied for the development of a potent anti-cancer agent, which is highly effective for angiogenesis-mediated diseases covering cancer, rheumatoid arthritis, psoriasis, ocular angiogenic disease, etc.
摘要翻译：本发明提供了一种新型的血管生成抑制剂LK68，其氨基酸序列与人载脂蛋白（a）三环结构域IV36，IV37和V38相同，编码LK68的cDNA序列，包含cDNA的重组表达载体，转化的重组微生物用重组表达载体和LK68作为抗癌剂的新用途和治疗血管生成介导的疾病的方法。 LK68，LK6，LK7和LK8表现出对培养的内皮细胞增殖以及内皮细胞迁移的抑制活性。 LK68及其单克隆也抑制鸡胚绒毛尿囊膜（CAM）毛细血管的正常发育。还表明，LK68的全身给药导致原发性肿瘤生长的抑制，其与抑制肿瘤诱导的血管发生相关。因此，LK68蛋白，其单克隆或其功能等同物可用于开发有效的抗癌剂，其对于涵盖癌症，类风湿性关节炎，牛皮癣，眼血管生成疾病等的血管生成介导的疾病是非常有效的。

2. 发明授权

US06743428B1 Angiogenesis inhibitor 失效
标题翻译：血管生成抑制剂
公开(公告)号：US06743428B1
公开(公告)日：2004-06-01
申请号：US10088548
申请日：2002-03-15
申请人： Jihoon Chang , Jang Seong Kim , Eun Jeong Park , Jung-sun Yum , Soo-Il Chung
发明人： Jihoon Chang , Jang Seong Kim , Eun Jeong Park , Jung-sun Yum , Soo-Il Chung
IPC分类号： A61K3900
CPC分类号： C07K14/4703 , A61K38/00
摘要： The present invention provides a novel angiogenesis inhibitor, LK68 whose amino acid sequence is identical with the human apolipoprotein (a) kringle domains IV36, IV37 and V38, a cDNA sequence encoding the LK68, a recombinant expression vector comprising the cDNA, a recombinant microorganism transformed with the recombinant expression vector and a novel use of the LK68 as an anticancer agent and a method for treating angiogenesis-mediated disease. LK68, LK6, LK7 and LK8 exhibit inhibitory activities on the cultured endothelial cell proliferation as well as on the endothelial cell migration. LK68 and its single kringles also inhibit the normal development of capillaries in the chick embryo chorioallantoic membrane (CAM). It was also showed that systemic administration of LK68 causes the inhibition of primary tumor growth, which is correlated with a suppression of tumor-induced angiogenesis. Accordingly, LK68 protein, its single kringles or their functional equivalents may be applied for the development of a potent anti-cancer agent, which is highly effective for angiogenesis-mediated diseases covering cancer, rheumatoid arthritis, psoriasis, ocular angiogenic disease, etc.
摘要翻译：本发明提供了一种新型的血管生成抑制剂LK68，其氨基酸序列与人载脂蛋白（a）三环结构域IV36，IV37和V38相同，编码LK68的cDNA序列，包含cDNA的重组表达载体，转化的重组微生物用重组表达载体和LK68作为抗癌剂的新用途和治疗血管生成介导的疾病的方法。 LK68，LK6，LK7和LK8表现出对培养的内皮细胞增殖以及内皮细胞迁移的抑制活性。 LK68及其单克隆也抑制鸡胚绒毛尿囊膜（CAM）毛细血管的正常发育。还表明，LK68的全身给药导致原发性肿瘤生长的抑制，其与抑制肿瘤诱导的血管发生相关。因此，LK68蛋白，其单克隆或其功能等同物可用于开发有效的抗癌剂，其对于涵盖癌症，类风湿性关节炎，牛皮癣，眼血管生成疾病等的血管生成介导的疾病是非常有效的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式